Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.12
ANGO's Cash to Debt is ranked lower than
53% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. ANGO: 0.12 )
ANGO' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: 0.12

Equity to Asset 0.67
ANGO's Equity to Asset is ranked higher than
76% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. ANGO: 0.67 )
ANGO' s 10-Year Equity to Asset Range
Min: 0.06   Max: 0.94
Current: 0.67

0.06
0.94
Interest Coverage 1.35
ANGO's Interest Coverage is ranked lower than
55% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.61 vs. ANGO: 1.35 )
ANGO' s 10-Year Interest Coverage Range
Min: 1.35   Max: 74.68
Current: 1.35

1.35
74.68
F-Score: 5
Z-Score: 1.67
M-Score: -2.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 2.07
ANGO's Operating margin (%) is ranked higher than
64% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.44 vs. ANGO: 2.07 )
ANGO' s 10-Year Operating margin (%) Range
Min: -10   Max: 13.14
Current: 2.07

-10
13.14
Net-margin (%) -0.18
ANGO's Net-margin (%) is ranked higher than
62% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.65 vs. ANGO: -0.18 )
ANGO' s 10-Year Net-margin (%) Range
Min: -8.13   Max: 8.75
Current: -0.18

-8.13
8.75
ROE (%) -0.12
ANGO's ROE (%) is ranked higher than
62% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. ANGO: -0.12 )
ANGO' s 10-Year ROE (%) Range
Min: -2.72   Max: 79.7
Current: -0.12

-2.72
79.7
ROA (%) -0.08
ANGO's ROA (%) is ranked higher than
63% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.24 vs. ANGO: -0.08 )
ANGO' s 10-Year ROA (%) Range
Min: -2.38   Max: 7.62
Current: -0.08

-2.38
7.62
ROC (Joel Greenblatt) (%) 5.71
ANGO's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. ANGO: 5.71 )
ANGO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -21.37   Max: 32.64
Current: 5.71

-21.37
32.64
Revenue Growth (%) 4.00
ANGO's Revenue Growth (%) is ranked higher than
70% of the 248 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. ANGO: 4.00 )
ANGO' s 10-Year Revenue Growth (%) Range
Min: 3.2   Max: 25.2
Current: 4

3.2
25.2
EBITDA Growth (%) -13.30
ANGO's EBITDA Growth (%) is ranked higher than
59% of the 210 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.40 vs. ANGO: -13.30 )
ANGO' s 10-Year EBITDA Growth (%) Range
Min: -33.8   Max: 31.3
Current: -13.3

-33.8
31.3
» ANGO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ANGO Guru Trades in Q1 2013

Mario Gabelli 170,000 sh (+2.39%)
Chuck Royce 873,425 sh (+0.34%)
Steven Cohen Sold Out
Jim Simons 75,100 sh (-53.21%)
» More
Q2 2013

ANGO Guru Trades in Q2 2013

Chuck Royce 946,103 sh (+8.32%)
Mario Gabelli 145,000 sh (-14.71%)
Jim Simons 17,946 sh (-76.1%)
» More
Q3 2013

ANGO Guru Trades in Q3 2013

Joel Greenblatt 16,031 sh (New)
Jim Simons 92,723 sh (+416.68%)
Chuck Royce 958,403 sh (+1.3%)
Mario Gabelli 110,000 sh (-24.14%)
» More
Q4 2013

ANGO Guru Trades in Q4 2013

Steven Cohen 161,069 sh (New)
Jim Simons 186,046 sh (+100.65%)
Joel Greenblatt Sold Out
Mario Gabelli 105,000 sh (-4.55%)
Chuck Royce 812,776 sh (-15.19%)
» More
» Details

Insider Trades

Latest Guru Trades with ANGO

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Sold Out 0.01%$13.38 - $16.71 $ 14.36-7%0
Joel Greenblatt 2013-09-30 New Buy0.01%$10.9 - $13.55 $ 14.3622%16031
Mario Gabelli 2013-09-30 Reduce -24.14%$10.9 - $13.55 $ 14.3622%110000
Joel Greenblatt 2012-09-30 Sold Out 0.12%$10.41 - $12.66 $ 14.3626%0
Mario Gabelli 2012-09-30 Add 22.25%$10.41 - $12.66 $ 14.3626%165032
Joel Greenblatt 2012-03-31 Add 89.16%0.07%$12.22 - $14.63 $ 14.3619%140154
Joel Greenblatt 2011-09-30 Add 58.28%0.05%$12.81 - $15.44 $ 14.363%63774
Mario Gabelli 2011-09-30 Reduce -49.13%0.01%$12.81 - $15.44 $ 14.363%103000
Joel Greenblatt 2011-03-31 Add 169.35%0.11%$15.07 - $17.4 $ 14.36-12%39233
Mario Gabelli 2011-03-31 Reduce -52.36%0.03%$15.07 - $17.4 $ 14.36-12%247560
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.90
ANGO's P/B is ranked higher than
95% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. ANGO: 0.90 )
ANGO' s 10-Year P/B Range
Min: 0.64   Max: 6.67
Current: 0.9

0.64
6.67
P/S 1.40
ANGO's P/S is ranked higher than
79% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.60 vs. ANGO: 1.40 )
ANGO' s 10-Year P/S Range
Min: 1.03   Max: 5.62
Current: 1.4

1.03
5.62
PFCF 22.70
ANGO's PFCF is ranked higher than
74% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.00 vs. ANGO: 22.70 )
ANGO' s 10-Year PFCF Range
Min: 8.87   Max: 285.43
Current: 22.7

8.87
285.43
EV-to-EBIT 166.70
ANGO's EV-to-EBIT is ranked lower than
75% of the 247 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.32 vs. ANGO: 166.70 )
ANGO' s 10-Year EV-to-EBIT Range
Min: 9.2   Max: 186
Current: 166.7

9.2
186
Shiller P/E 57.40
ANGO's Shiller P/E is ranked lower than
69% of the 127 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.28 vs. ANGO: 57.40 )
ANGO' s 10-Year Shiller P/E Range
Min: 33.31   Max: 94.15
Current: 57.4

33.31
94.15

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.80
ANGO's Price/DCF (Projected) is ranked higher than
91% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. ANGO: 0.80 )
ANGO' s 10-Year Price/DCF (Projected) Range
Min: 0.54   Max: 1.09
Current: 0.8

0.54
1.09
Price/Median PS Value 0.80
ANGO's Price/Median PS Value is ranked higher than
85% of the 268 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. ANGO: 0.80 )
ANGO' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 2.76
Current: 0.8

0.6
2.76
Earnings Yield (Greenblatt) 0.60
ANGO's Earnings Yield (Greenblatt) is ranked lower than
68% of the 226 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.40 vs. ANGO: 0.60 )
ANGO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 10.9
Current: 0.6

0.5
10.9
Forward Rate of Return (Yacktman) -14.16
ANGO's Forward Rate of Return (Yacktman) is ranked higher than
58% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. ANGO: -14.16 )
ANGO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -15.1   Max: 5.7
Current: -14.16

-15.1
5.7

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:UG2.Germany
AngioDynamics Inc. was incorporated in 1988 in Delaware. The Company designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company is organized in two segments: Vascular and Oncology/Surgery. The Oncology/Surgery Division includes Radiofrequency Ablation (RFA) and NanoKnife product lines. This division also includes the microwave ablation technology products obtained through the acquisition of Microsulis Medical Ltd. The Vascular division manages Fluid Management, Venous, AngioVac, Angiographic, PTA, Drainage, Thrombolytic, Micro Access Kits, Dialysis, PICC and Port product lines. The Company's product offering includes the NAMIC Fluid Management portfolio. The NAMIC product line includes an extensive offering of manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers and interventional accessories. The devices are utilized together and allow clinicians to aspirate or inject contrast, saline, remove waste and monitor invasive blood pressures throughout the procedure. The venous products consist of our VenaCure EVLT laser system and Sotradecol. The AngioVac devices are for use with other manufacturer's off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of a extracorporeal bypass procedure for up to six hours. Thrombolytic catheters are used to deliver thrombolytic agents, which are drugs that dissolve blood clots in hemodialysis access grafts, arteries, veins and surgical bypass grafts. The micro access sets provide interventional physicians a smaller introducer system for minimally-invasive procedures. Image-guided vascular access, or IGVA, involves the use of advanced imaging equipment to guide the placement of catheters that deliver primarily short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system. Radiofrequency Ablation (RFA) products use radiofrequency energy to provide a minimally invasive approach to ablating solid cancerous or benign tumors. The NanoKnife Ablation System is for the surgical ablation of soft tissue. The NanoKnife Ablation System utilizes low energy direct current electrical pulses to permanently open pores in target cell membranes. The treated tissue is then removed by the body's natural processes in a matter of weeks, mimicking natural cell death. The Acculis Microwave Tissue Ablation (MTA) System complements the full range of ablative technologies. The Company competes with Boston Scientific Corporation; Cook Medical; Cordis Corporation, a subsidiary of Johnson & Johnson, Inc.; C.R. Bard; Medical Components, Inc., or Medcomp; Arrow International, a subsidiary of TeleFlex Medical; Smith's Medical, a subsidiary of Smiths Group PLC; Vascular Solutions; Covidien subsidiaries (Kendall, VNUS, EV3) and M

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide